January 13, 2005
In response to the growing number of inquiries about the independent panel hearing for ProHeart® 6, (moxidectin) we are providing the following information, which was just released by the U.S. Food and Drug Administration.
The independent advisory panel, tasked with reviewing and evaluating ProHeart 6 data, has been slated to convene Monday, January 31, 2005, from 8 a.m. to 5:30 p.m. The meeting will be held at the DoubleTree Hotel in Rockville, MD.
The panel will thoroughly examine and assess product data presented by Fort Dodge Animal Health and scientific experts, as well as representatives from the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM). Fort Dodge will promptly communicate the committee’s recommendation to veterinarians, other animal health professionals and consumers.
For more information about hearing procedures, please visit http://www.fda.gov/oc/advisory/accalendar/2005/
cvm12548d013105.html.
Fort Dodge is pleased to participate in this process. We remain confident in the safety and efficacy of ProHeart 6, and believe science will prevail in this matter.
Regards,
Brent Standridge
Senior Vice President
North America Sales & Marketing
